新抗原标靶治疗市场按治疗方式、治疗方法、给药途径、年龄组、目标疾病适应症和最终用户划分 - 全球预测 2025-2030

预计2024年肿瘤新抗原标靶治疗市值将达45.7亿美元，并将从2025年的53亿美元成长至2030年的112.4亿美元，复合年增长率为16.16%。

主要市场统计数据
基准年2024年	45.7亿美元
预计2025年	53亿美元
预测年份 2030	112.4亿美元
复合年增长率（%）	16.16%

探索新抗原标靶治疗的前所未有的潜力，彻底改变全球个人化免疫肿瘤治疗模式

新抗原标靶治疗已成为癌症研究的前沿，为癌症治疗提供了高度个人化的方案。这些治疗方法利用肿瘤特异性突变，旨在刺激强大的免疫反应，从而区分恶性细胞和健康细胞。这种模式转移解决了传统免疫疗法的局限性，降低了脱靶毒性，并提高了个人化抗肿瘤疗效。

识别影响新抗原标靶治疗在研究和临床应用中前景的关键转型转变

在生物技术进步和对肿瘤免疫学深入理解的推动下，肿瘤新抗原标标靶治疗领域正在经历快速变化。近年来，多学科专业知识的空前融合，使得抗原发现流程和给药平台的快速优化成为可能。这种协同效应加速了从实验室到临床的转化，多个早期项目在固态和骨髓恶性肿瘤中展现出良好的安全性和有效性。

评估2025年美国拟议关税对肿瘤新抗原治疗供应链和研究投资的累积影响

美国政府提案对关键原料、试剂和成品生技药品征收关税，这给肿瘤新抗原治疗开发商带来了复杂的挑战。许多供应链依赖专用酵素、细胞培养基和一次性系统，而这些产品都需要缴纳进口关税。随着这些成本压力的累积，研发预算面临严重限制，这可能会减缓研究进度并延长临床试验时间。

从多方面的市场区隔中获得关键见解，以发现针对新抗原的治疗方式和使用案例的机会

市场区隔分析揭示了可为产品开发和商业化策略提供资讯的关键差异化因素。根据治疗方式，主要分为两大类：过继性细胞疗法和个人化肿瘤抗原疫苗。在过继性细胞疗法中，不同的子类别，例如嵌合体抗原受体T细胞疗法、基于T细胞受体的疗法和肿瘤浸润淋巴细胞疗法，各自都存在各自的生产挑战和临床特征。同时，疫苗平台涵盖基于树突状细胞的製剂、具有DNA或RNA有效载荷的核酸构建体以及合成长肽製剂，每种製剂都利用不同的递送和佐剂系统来优化免疫抗原性。

了解美洲、中东/非洲和亚太地区新抗原治疗扩展的区域动态和驱动因素

区域动态在肿瘤新抗原标标靶治疗的采用和发展中发挥关键作用。美洲地区对生物技术中心、综合医疗保健系统和患者支持网络的大力投资，为早期临床试验和商业性上市创造了肥沃的土壤。该地区的监管机构也展现出灵活性，提供快速审查途径，以促进新型免疫疗法的快速探索。

评估领先生物製药公司推动以新抗原为重点的癌症疗法创新和商业化的策略性倡议

领先的生物製药公司正在策略性地投资新抗原发现平台、生产规模扩大和临床开发伙伴关係，以确保先发优势。创新新兴企业正利用专有的机器学习演算法，以高置信度预测新表位，从而脱颖而出；而大型公司则利用其製造专业知识，简化自体细胞处理的工作流程。

产业领导者实施可行的策略来应对新出现的挑战并利用新抗原治疗中的机会

产业领导者应优先将高阶分析技术整合到肿瘤新抗原发现工作流程中。投资高通量表位筛检和强大的生物资讯学流程，可以帮助公司提高候选药物的选择性，缩短开发週期，并最终降低临床结果的风险。将资源策略性地配置到模组化製造平台，可以提高营运灵活性，并降低每批产品的资本支出。

概述强大的多阶段调查方法，以检验新抗原标标靶治疗市场分析的基础数据和见解

本分析所采用的调查方法将全面的二手资料研究与针对性的一手资料研究结合。首先，进行了广泛的文献综述和专利态势评估，以确定关键的技术进步和智慧财产权趋势。监管申请、临床试验註册中心和科学会议论文集提供了处于不同研发阶段的疗法的基础资料库。

综合关键发现和影响来确定肿瘤新抗原标靶治疗的未来发展轨迹。

精准免疫学、先进製造和数据驱动型发现的融合，使新抗原标靶治疗成为癌症治疗领域的标誌性创新。本分析揭示了多样化的治疗模式、不断发展的法规以及策略联盟如何加速临床进展，并为更广泛的商业化做好准备。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 个人化免疫疗法需求不断增长推动新抗原创新
• 开发用于体内递送新抗原编码 mRNA 疗法的非病毒载体平台
• 新抗原疫苗与免疫查核点抑制剂联合治疗的出现
• 基于mRNA的肿瘤新抗原疫苗脂质奈米颗粒递送系统的进展
• 个体化肿瘤新抗原特异性T细胞受体治疗在进行性黑色素瘤的临床应用
• 技术进步推动肿瘤新抗原标标靶治疗市场成长
• 多表位新抗原递送系统在增强针对固态肿瘤的免疫反应的进展
• 指导个人化新抗原免疫治疗临床发展的不断发展的法规结构
• 人工智慧和基因组学改变新抗原的发现和开发
• 实施数位双胞胎模拟以预测患者特异性新抗原免疫参与

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

8. 新抗原标标靶治疗市场（依治疗方式）

• 过继性细胞疗法
  • CAR-T细胞疗法
  • T细胞受体（TCR）疗法
  • 肿瘤浸润淋巴细胞（TIL）
• 个人化新抗原疫苗
  • 树突状细胞（DC）疫苗
  • DNA/RNA疫苗
  • 胜肽（SLP）疫苗

9. 新抗原标标靶治疗市场（依治疗方法）

• 联合治疗
• 单药治疗

第 10 章 新抗原标靶治疗市场（依给药途径）

• 口服
• 肠外
  • 肌肉注射
  • 静脉
  • 皮下

第十一章 新抗原标靶治疗市场（依年龄层）

• 成人
• 老年人
• 孩子们

第十二章 肿瘤新抗原标标靶治疗市场（依目标疾病适应症）

• 骨癌
• 大肠直肠癌
• 妇科癌症
• 非小细胞肺癌
• 肾臟细胞癌

第十三章 新抗原标靶治疗市场（依最终用户）

• 学术和政府研究组织
• 医院和诊所
• 专科诊所

14.美洲新抗原标靶治疗市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

15. 欧洲、中东和非洲新抗原标靶治疗市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

16. 亚太地区新抗原标靶治疗市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十七章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol-Myers Squibb Company
  • CureVac NV
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics NV
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd

第十八章 研究人工智慧

第十九章 研究统计

第二十章 研究联络人

第21章 研究报导

第22章 附录

The Neoantigen Targeted Therapies Market was valued at USD 4.57 billion in 2024 and is projected to grow to USD 5.30 billion in 2025, with a CAGR of 16.16%, reaching USD 11.24 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 4.57 billion
Estimated Year [2025]	USD 5.30 billion
Forecast Year [2030]	USD 11.24 billion
CAGR (%)	16.16%

Exploring the Unprecedented Potential of Neoantigen Targeted Therapies to Revolutionize Personalized Immuno-Oncology Treatment Paradigms Worldwide

Neoantigen targeted therapies have emerged at the forefront of oncology research, offering highly personalized approaches to cancer treatment. By harnessing unique tumor-specific mutations, these therapies aim to stimulate robust immune responses that distinguish malignant cells from their healthy counterparts. This paradigm shift addresses the limitations of conventional immunotherapies, reducing off-target toxicity and enhancing antitumor efficacy on an individual patient basis.

Researchers and clinicians have dedicated significant efforts to unraveling the molecular underpinnings of neoantigen recognition, enabling the design of adoptive cell therapies and bespoke vaccine platforms. As a result, academic centers are collaborating closely with biopharmaceutical innovators, accelerating the translation of preclinical discoveries into early-phase clinical trials. This collaborative dynamic sets the stage for a new era of precision oncology, where treatment regimens are tailored to genomic signatures rather than histological classifications alone.

Moreover, advancements in computational algorithms and next-generation sequencing have streamlined neoantigen identification, reducing the time required to formulate patient-specific therapeutics. With increasing regulatory support and streamlined manufacturing processes, the field is poised for rapid expansion, offering the promise of durable responses and improved survival for patients with diverse tumor indications.

Furthermore, as the global healthcare ecosystem places greater emphasis on value-based care, the cost-effectiveness and scalability of neoantigen therapies are under rigorous evaluation. Stakeholders are assessing manufacturing workflows, quality control standards, and logistics to ensure that these bespoke treatments can be delivered at scale without compromising safety or efficacy.

Identifying the Key Transformative Shifts Shaping the Neoantigen Targeted Therapy Landscape Across Research and Clinical Application Domains

The landscape of neoantigen targeted therapies is undergoing seismic transformation driven by advances in biotechnology and a deeper understanding of tumor immunology. Recent years have witnessed an unprecedented convergence of multidisciplinary expertise, enabling the rapid refinement of antigen discovery pipelines and the optimization of delivery platforms. This synergy has accelerated the transition from bench to bedside, with multiple early-stage programs demonstrating encouraging safety and efficacy profiles in solid and hematologic malignancies.

In parallel, the integration of artificial intelligence and machine learning into epitope prediction and neoantigen prioritization has further elevated the field's potential. These computational tools facilitate high-throughput screening and enhance the precision of immunogenic candidate selection. Consequently, developers are exploring novel constructs that combine adoptive cell therapies with antigen-specific vaccination strategies to amplify T cell responses and overcome immunosuppressive microenvironments.

Manufacturing innovations are also reshaping the therapeutic ecosystem. Modular and automated production platforms are reducing batch variability and turnaround times, while quality-by-design principles are ensuring consistent product attributes. Regulatory agencies have responded by issuing guidance frameworks that support accelerated pathways and adaptive trial designs, reflecting a growing recognition of the unique nature of personalized immunotherapies.

Looking ahead, strategic partnerships between biotech innovators, contract development and manufacturing organizations, and healthcare providers will be critical. These alliances will drive economies of scale, improve access to specialized infrastructure, and enable the simultaneous exploration of novel combinations, further solidifying neoantigen targeted therapies as a cornerstone of future oncologic care.

Assessing the Cumulative Impact of Proposed United States Tariffs on Neoantigen Therapy Supply Chains and Research Investments in 2025

Proposed tariffs by the United States government on key raw materials, reagents, and finished biologics present a complex set of challenges for neoantigen therapy developers. Many supply chains rely on specialized enzymes, cell culture media, and single-use systems that are subject to import duties. As these cost pressures accumulate, research and development budgets face tighter constraints, potentially slowing investigative efforts and prolonging time to clinic.

In response, companies are reevaluating sourcing strategies and exploring domestic manufacturing alternatives. Some biopharma organizations have initiated feasibility studies to repatriate critical production steps, aiming to insulate their operations from fluctuating international trade policies. While this approach can mitigate tariff exposure, it often requires substantial capital investment in infrastructure, workforce training, and quality assurance protocols.

Moreover, delays at customs checkpoints and increased documentation requirements can disrupt just-in-time manufacturing models, leading to extended lead times and idle production capacity. This dynamic underscores the importance of supply chain resilience and risk diversification, particularly for therapies with compressed clinical timelines.

Despite these headwinds, there are opportunities for innovation. Companies that streamline their vendor portfolios, adopt regional stockpiling strategies, and leverage strategic alliances with contract manufacturers stand to reduce overhead and maintain timeline commitments. In a broader context, the tariff environment may incentivize policymakers and industry stakeholders to collaborate on trade agreements that recognize the critical value of advanced therapies, ultimately fostering a more predictable regulatory and economic landscape.

Deriving Key Insights from Multifaceted Market Segmentation to Illuminate Opportunities in Neoantigen Targeted Therapeutic Modalities and Use Cases

Market segmentation analysis reveals critical differentiators that inform product development and commercialization strategies. Based on therapy modality, two primary categories emerge: adoptive cell therapies and personalized neoantigen vaccines. Within adoptive cell therapies, distinct subcategories such as chimeric antigen receptor T cell therapy, T cell receptor-based therapy, and tumor-infiltrating lymphocyte approaches each present unique manufacturing challenges and clinical profiles. Meanwhile, vaccine platforms span dendritic cell-based preparations, nucleic acid constructs employing DNA or RNA payloads, and synthetic long peptide formulations, each leveraging different delivery and adjuvant systems to optimize immunogenicity.

Examining treatment approach sheds light on the evolving balance between monotherapy regimens and combination protocols. Combination approaches pairing neoantigen-directed modalities with checkpoint inhibitors or targeted agents are increasingly prevalent, aiming to amplify antitumor responses while counteracting immunosuppressive signals within the tumor microenvironment.

Route of administration further delineates product positioning. Oral formulations are under exploration for select vaccine candidates, but parenteral delivery remains the mainstay. Intramuscular injection is favored for dendritic cell vaccines, whereas intravenous infusion is required for most autologous cell therapies, and subcutaneous administration is being trialed to enhance patient compliance in select peptide-based interventions.

Age group segmentation underscores differential therapeutic considerations for adult, geriatric, and pediatric populations. Variable immune system maturity and comorbidity profiles drive tailored dosing and safety monitoring frameworks. Likewise, diverse target disease indications-from bone cancers and colorectal malignancies to gynecological tumors, non-small cell lung cancer, and renal cell carcinoma-demand bespoke neoantigen selection algorithms and clinical trial designs.

Finally, the end-user landscape spans academic and government research institutes spearheading early discovery, hospitals and clinics delivering clinical care, and specialty centers providing advanced immunotherapy infusion services. Understanding the unique needs and purchasing behaviors across these settings is essential for market entry and commercialization planning.

Uncovering Regional Dynamics and Growth Drivers Across the Americas, Europe Middle East & Africa, and Asia-Pacific in Neoantigen Therapy Expansion

Regional dynamics play a pivotal role in shaping the adoption and development of neoantigen targeted therapies. In the Americas, robust investment in biotech hubs, integrated healthcare systems, and patient advocacy networks has created fertile ground for early-phase clinical trials and commercial launches. Regulatory bodies in this region have also demonstrated flexibility, offering expedited review pathways that facilitate rapid investigation of novel immunotherapies.

Conversely, the Europe, Middle East & Africa corridor presents a heterogeneous environment. Western European markets benefit from well-established reimbursement frameworks and centralized regulatory bodies, while emerging Middle Eastern and African countries are increasingly investing in advanced biomanufacturing infrastructure to address regional disease burdens. Collaborative consortia and cross-border trial networks are leveraging these developments to broaden patient access and diversify trial populations.

Across Asia-Pacific, government initiatives targeting biotech innovation, coupled with expanding healthcare coverage and a large patient pool, are driving significant momentum. Countries in this region are particularly focused on building local manufacturing capabilities and forging public-private partnerships to accelerate translational research. These efforts are complemented by tailored regulatory adaptations that address the unique logistical and cultural considerations inherent to personalized therapies.

Collectively, these regional insights underscore the importance of localized market entry strategies, adaptive pricing models, and strategic alliances with governmental and academic stakeholders. Companies that navigate these diverse dynamics effectively will be well positioned to capture value and drive global expansion.

Evaluating Strategic Movements of Leading Biopharma Players Driving Innovation and Commercialization in Neoantigen Focused Cancer Therapies

Leading biopharmaceutical companies are strategically investing in neoantigen discovery platforms, manufacturing scale-up, and clinical development partnerships to secure first-mover advantages. Innovative startups are differentiating through proprietary machine learning algorithms that predict high-confidence neoepitopes, while larger organizations are leveraging their manufacturing expertise to streamline autologous cell process workflows.

Several publicly traded entities have announced collaborations with academic centers to access patient biopsy repositories and accelerate biomarker validation. These alliances not only enhance candidate selection but also establish real-world evidence generation frameworks that support payer engagement discussions. Concurrently, contract development and manufacturing organizations are expanding cleanroom capacity and introducing modular production suites specifically tailored for personalized immunotherapies.

In the vaccine segment, companies with nucleic acid expertise are repurposing existing RNA platforms, adapting lipid nanoparticle formulations to accommodate neoantigen payloads, and optimizing cold chain logistics. This approach benefits from established supply networks and offers a rapid response capability for individualized therapy manufacturing.

Adoptive cell therapy pioneers are pursuing allogeneic "off-the-shelf" strategies to mitigate time-to-treatment challenges, while ensuring robust safety switches and T cell persistence mechanisms. Their efforts are complemented by ongoing investment in cell editing technologies to enhance target specificity and reduce cytokine release syndrome incidence. The combined focus on innovative modality development, scalable manufacturing, and comprehensive safety profiling is accelerating the emergence of commercially viable neoantigen products poised to transform oncology care.

Implementing Actionable Strategies for Industry Leaders to Navigate Emerging Challenges and Capitalize on Opportunities in Neoantigen Therapeutics

Industry leaders should prioritize the integration of advanced analytics into their neoantigen discovery workflows. By investing in high-throughput epitope screening and robust bioinformatic pipelines, organizations can improve candidate selectivity, reduce development cycles, and ultimately de-risk clinical outcomes. Strategic allocation of resources toward modular manufacturing platforms will enhance operational agility and reduce capital expenditure per product batch.

Fostering cross-sector collaborations is equally critical. Partnerships between biotech innovators, academic institutions, and contract manufacturers can unlock shared infrastructure, accelerate proof-of-concept studies, and facilitate rapid scale-up. Leaders should also engage with regulatory agencies early to align on adaptive trial designs and breakthrough designation opportunities, thereby ensuring that novel therapies reach patients without unnecessary delays.

To maximize commercial success, it is imperative to develop differentiated value propositions that address payer concerns around cost-effectiveness and real-world outcomes. Implementing longitudinal patient registries and health economics studies will support reimbursement negotiations and demonstrate long-term benefits over standard-of-care. Additionally, embracing flexible pricing models and risk-sharing agreements can alleviate financial barriers for healthcare providers.

Finally, executives must cultivate talent with dual expertise in immunology and bioprocess engineering. Building cross-functional teams capable of navigating both scientific and operational complexities will position organizations to respond swiftly to emerging data, optimize manufacturing protocols, and deliver personalized therapies at scale.

Outlining a Robust Multi-Phase Research Methodology to Validate Data and Insights Underpinning the Neoantigen Targeted Therapies Market Analysis

The research methodology underpinning this analysis combines comprehensive secondary research with targeted primary validation. Initially, extensive literature reviews and patent landscape assessments were conducted to identify key technological advancements and intellectual property trends. Regulatory filings, clinical trial registries, and scientific conference proceedings provided a foundational database of therapeutics in various stages of development.

Subsequently, in-depth interviews with senior executives, scientific directors, and manufacturing leads at companies active in neoantigen modalities enriched the dataset. These discussions focused on platform capabilities, pipeline prioritization, and strategic partnerships, offering nuanced perspectives that are not readily available in public domains. Additional insights were gathered through consultations with regulatory experts to clarify evolving approval pathways and policy initiatives.

Quantitative data collection included benchmarking of manufacturing costs, reagent sourcing challenges, and supply chain lead times across different geographic regions. This information was triangulated against proprietary databases and industry reports to ensure accuracy. Lastly, all findings were subjected to an internal peer review process, incorporating feedback from immuno-oncology specialists to validate technical content and refine analytical frameworks.

Synthesizing Key Findings and Implications to Highlight the Future Trajectory of Neoantigen Targeted Therapies in Oncology Care

The convergence of precision immunology, advanced manufacturing, and data-driven discovery has positioned neoantigen targeted therapies as a defining innovation in cancer treatment. This analysis highlights how modality diversification, regulatory evolution, and strategic collaborations are collectively accelerating clinical progress and preparing the market for broader commercialization.

While challenges such as supply chain resilience, tariff impacts, and reimbursement frameworks require careful management, the underlying scientific momentum and unmet medical need create a conducive environment for sustained growth. Companies that strategically invest in scalable infrastructure, prioritize robust candidate selection, and maintain adaptive trial designs will unlock new avenues for patient benefit.

Looking forward, the integration of combination regimens, expansion into underserved patient populations, and ongoing optimization of safety profiles will be pivotal. The ability to deliver personalized therapies with precise targeting and manageable manufacturing timelines will ultimately determine market leadership and therapeutic impact.

By synthesizing the key insights presented in this report, stakeholders can better navigate the complexities of neoantigen targeted therapy development and deployment. Armed with a clear understanding of segment-specific dynamics, regional nuances, and competitive landscapes, decision-makers are well positioned to drive the next wave of innovation in immuno-oncology treatment.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Rising demand for personalized immunotherapies driving neoantigen innovation
• 5.2. Development of non-viral vector platforms for in vivo delivery of neoantigen-encoding mRNA therapies
• 5.3. Emergence of combination regimens pairing neoantigen vaccines with immune checkpoint blockade therapies
• 5.4. Advances in lipid nanoparticle delivery systems for mRNA-based neoantigen vaccines in oncology
• 5.5. Clinical translation of personalized neoantigen-specific T cell receptor therapies in advanced melanoma patients
• 5.6. Technological advances fueling growth in neoantigen-targeted therapy market
• 5.7. Advances in multi-epitope neoantigen delivery systems enhancing immune responses against solid tumors
• 5.8. Regulatory framework evolution guiding clinical development of individualized neoantigen immunotherapies
• 5.9. AI and genomics transforming neoantigen discovery and development
• 5.10. Implementation of digital twin simulations to predict patient-specific neoantigen immune engagement in silico

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Neoantigen Targeted Therapies Market, by Therapy Modality

• 8.1. Introduction
• 8.2. Adoptive Cell Therapy
  • 8.2.1. CAR-T Cell Therapy
  • 8.2.2. T Cell Receptor (TCR) Therapy
  • 8.2.3. Tumor-infiltrating lymphocytes (TIL)
• 8.3. Personalized Neoantigen Vaccines
  • 8.3.1. Dendritic Cell (DC) Vaccines
  • 8.3.2. DNA/ RNA-based Vaccines
  • 8.3.3. Peptide (SLP) Vaccines

9. Neoantigen Targeted Therapies Market, by Treatment Approach

• 9.1. Introduction
• 9.2. Combination Therapy
• 9.3. Monotherapy

10. Neoantigen Targeted Therapies Market, by Route of Administration

• 10.1. Introduction
• 10.2. Oral
• 10.3. Parenteral
  • 10.3.1. Intramuscular
  • 10.3.2. Intravenous
  • 10.3.3. Subcutaneous

11. Neoantigen Targeted Therapies Market, by Age Group

• 11.1. Introduction
• 11.2. Adult
• 11.3. Geriatric
• 11.4. Pediatric

12. Neoantigen Targeted Therapies Market, by Target Disease Indication

• 12.1. Introduction
• 12.2. Bone Cancer
• 12.3. Colorectal Cancer
• 12.4. Gynecological Cancer
• 12.5. Non-Small Cell Lung Cancer
• 12.6. Renal Cell Carcinoma

13. Neoantigen Targeted Therapies Market, by End-User

• 13.1. Introduction
• 13.2. Academic & Government Research Institutes
• 13.3. Hospitals & Clinics
• 13.4. Specialty Clinics

14. Americas Neoantigen Targeted Therapies Market

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. Argentina

15. Europe, Middle East & Africa Neoantigen Targeted Therapies Market

• 15.1. Introduction
• 15.2. United Kingdom
• 15.3. Germany
• 15.4. France
• 15.5. Russia
• 15.6. Italy
• 15.7. Spain
• 15.8. United Arab Emirates
• 15.9. Saudi Arabia
• 15.10. South Africa
• 15.11. Denmark
• 15.12. Netherlands
• 15.13. Qatar
• 15.14. Finland
• 15.15. Sweden
• 15.16. Nigeria
• 15.17. Egypt
• 15.18. Turkey
• 15.19. Israel
• 15.20. Norway
• 15.21. Poland
• 15.22. Switzerland

16. Asia-Pacific Neoantigen Targeted Therapies Market

• 16.1. Introduction
• 16.2. China
• 16.3. India
• 16.4. Japan
• 16.5. Australia
• 16.6. South Korea
• 16.7. Indonesia
• 16.8. Thailand
• 16.9. Philippines
• 16.10. Malaysia
• 16.11. Singapore
• 16.12. Vietnam
• 16.13. Taiwan

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Achilles Therapeutics Limited
  • 17.3.2. Agenus Inc.
  • 17.3.3. AstraZeneca plc
  • 17.3.4. BioNTech SE
  • 17.3.5. Bristol-Myers Squibb Company
  • 17.3.6. CureVac N.V.
  • 17.3.7. Eli Lilly and Company
  • 17.3.8. EpiVax, Inc.
  • 17.3.9. F. Hoffmann-La Roche AG
  • 17.3.10. Genentech, Inc.
  • 17.3.11. Genocea Biosciences, Inc.
  • 17.3.12. Gilead Sciences, Inc.
  • 17.3.13. GlaxoSmithKline plc
  • 17.3.14. Gritstone bio, Inc.
  • 17.3.15. Immatics N.V.
  • 17.3.16. Immunomic Therapeutics, Inc.
  • 17.3.17. IOVANCE Biotherapeutics, Inc.
  • 17.3.18. Medigene AG
  • 17.3.19. Merck & Co., Inc.
  • 17.3.20. Moderna, Inc.
  • 17.3.21. Neon Therapeutics, Inc.
  • 17.3.22. Nykode Therapeutics
  • 17.3.23. Pfizer Inc.
  • 17.3.24. Precision Biologics
  • 17.3.25. Valo Therapeutics Ltd

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

• FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 18. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 20. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 26. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 27. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHAI
• FIGURE 28. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHSTATISTICS
• FIGURE 29. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHCONTACTS
• FIGURE 30. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 80. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 81. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 82. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 83. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 84. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 85. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 86. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 87. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 88. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 89. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 90. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 91. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 92. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 93. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 94. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 99. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 100. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 101. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 102. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 103. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 104. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 105. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 106. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 107. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 108. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 109. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 110. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 111. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 112. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 113. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 114. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 119. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 120. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 121. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 122. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 123. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 124. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 125. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 126. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 127. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 128. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 129. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 130. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 131. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 132. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 133. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 134. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 135. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 136. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 137. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 138. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 139. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 140. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 141. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 142. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 143. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 144. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 145. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 146. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 147. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 148. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 149. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 150. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 151. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 152. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 155. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 156. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 157. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 158. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 159. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 160. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 161. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 162. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 163. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 164. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 165. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 166. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 167. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 168. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 169. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 170. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 171. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 172. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 173. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 174. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 175. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 176. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 177. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 178. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 179. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 180. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 181. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 182. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 183. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 184. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 185. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 186. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 187. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 188. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 189. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 190. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 211. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 212. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 213. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 214. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 215. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 216. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 217. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 218. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 219. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 220. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 221. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 222. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 223. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 224. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 225. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 226. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 228. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 229. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 230. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 231. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 232. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 233. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 234. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 235. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 236. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 237. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 238. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 239. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 240. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 241. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 243. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 244. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 245. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 246. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 247. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 248. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 249. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 250. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 251. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 252. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 253. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 254. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 255. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 256. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 257. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 258. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 259. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 260. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 261. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 262. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 263. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 265. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 266. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 267. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 268. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 269. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 270. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 271. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 272. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 273. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 274. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 275. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 276. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
• TABLE 277. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 278. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 279. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
• TABLE 280. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
• TABLE 281. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 282. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 283. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
• TABLE 284. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
• TABLE 285. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
• TABLE 286. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
• TABLE 287. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
• TABLE 288. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
• TABLE 289. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
• TABLE 290. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
• TABLE 291. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 292. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
• TABLE 293. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
• TABLE 294. ITALY NE